0001538864-19-000001.txt : 20190108 0001538864-19-000001.hdr.sgml : 20190108 20190108145158 ACCESSION NUMBER: 0001538864-19-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190108 DATE AS OF CHANGE: 20190108 EFFECTIVENESS DATE: 20190108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QT ULTRASOUND LLC CENTRAL INDEX KEY: 0001538864 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-308329 FILM NUMBER: 19515709 BUSINESS ADDRESS: STREET 1: 3 HAMILTON LANDING STREET 2: SUITE 160 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4158427242 MAIL ADDRESS: STREET 1: 3 HAMILTON LANDING STREET 2: SUITE 160 CITY: NOVATO STATE: CA ZIP: 94949 FORMER COMPANY: FORMER CONFORMED NAME: CVUS Clinical Trials, LLC DATE OF NAME CHANGE: 20120106 D/A 1 primary_doc.xml X0708 D/A LIVE 0001538864 QT ULTRASOUND LLC 3 HAMILTON LANDING SUITE 160 NOVATO CA CALIFORNIA 94949 4158427242 DELAWARE CVUS Clinical Trials, LLC Limited Liability Company true John C. Klock 3 Hamilton Landing Suite 160 Novato CA CALIFORNIA 94949 Executive Officer Director Chief Executive Officer and Manager David C. Gentile 331 Cleveland Street Clearwater FL FLORIDA 33755 Director Manager Kenneth G. Hungerford 2471 Riveredge Drive Grand Rapids MI MICHIGAN 49456 Director Manager Carl M. Jandernoa 171 Monroe Ave. N.W. Suite 410 Grand Rapids MI MICHIGAN 49503 Director Manager Robert Y. Kessler 187 Irwin St. Brooklyn NY NEW YORK 11235 Director Manager John J. Meilner 171 Monroe Ave. N.W. Suite 410 Grand Rapids MI MICHIGAN 49503 Director Manager Other Health Care $1 - $1,000,000 06b true 0001538864-18-000002 2018-05-25 true true false 50000 Ascendant Alternative Strategies, LLC 283881 None None 535 West 24th Street 4th Floor New York NY NEW YORK 10011 All States false 70000000 25824630 44175370 Includes $14,000,000 overallotment. false 251 7000000 true 0 Does not include (i) 3% cost allowance of which 1.5% is non accountable, or (ii) 2% warrants with exercise price equivalent to placement price. 0 true Proceeds are used for clinical trials; FDA regulatory expenses; engineering, research and development; imaging centers build-out; and operations. The executive officers may receive compensation from the Issuer's investment proceeds. false QT ULTRASOUND LLC John C. Klock John C. Klock Chief Executive Officer and Manager 2019-01-08